Aug 15, 2025
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
Aug 08, 2025
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
Aug 08, 2025
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
Aug 08, 2025
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
Apr 28, 2025
Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer
Apr 22, 2025
Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025
Feb 27, 2025
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates
Dec 23, 2024
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
Dec 03, 2024
U.S. District Court Upholds Validity of CINVANTI® Patents
Nov 04, 2024
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
Oct 29, 2024
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
Sep 03, 2024
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
Aug 06, 2024
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
Jul 15, 2024
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
May 29, 2024
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
May 07, 2024
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
May 07, 2024
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
Apr 11, 2024
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
Feb 28, 2024
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
Jan 07, 2024
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain